Princess Alexandra Hospital

UK-based NHS Trust Saves up to £3M in IT Costs Over 5 Years and Improves the Digital Experience for Clinicians with Alluvio Aternity from Riverbed

Retrieved on: 
Mercoledì, Ottobre 18, 2023
Apps, Applications, Technology, Hospitals, Health Technology, Software, Networks, Hardware, Health, Data Management, Wood, Gentlemen's agreement, Princess Alexandra Hospital NHS Trust, DEM, Essex Hospital, Crash, Electricity, Carbon footprint, UK, Trust, Microsoft Windows, Partnership, Apple, Hospital, Princess Alexandra Hospital, SLA, ICT, Hospital Insurance and Diagnostic Services Act, Patient, Automation, Nursing, Heating, ventilation, and air conditioning, Stream bed

The organisation’s IT team is responsible for delivering excellent digital experience to over 3,700 staff – including doctors, clinicians, community nurses and more.

Key Points: 
  • The organisation’s IT team is responsible for delivering excellent digital experience to over 3,700 staff – including doctors, clinicians, community nurses and more.
  • Since the implementation of Aternity, the Trust has been able to better understand and improve the clinician experience and forge efficient patient pathways.
  • The Trust is projected to save £2.5 to £3 million in IT costs over a 5-year period with Alluvio Aternity from Riverbed.
  • Jeffrey Wood, Deputy Director of ICT at The Princess Alexandra Hospital NHS Trust, explains: ‘‘Alluvio Aternity from Riverbed is able to highlight where our real issues are.

RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer

Retrieved on: 
Lunedì, Ottobre 9, 2023
Lung cancer, ASX, Safety, GenesisCare, Princess Alexandra Hospital, Patient, Pharmaceutical industry, Medical imaging, NSCLC

The dose escalation trial of RAD204, which targets PDL1-positive NSCLC, is designed to evaluate the safety and efficacy of this novel radiotherapeutic in eligible individuals with lung cancer.

Key Points: 
  • The dose escalation trial of RAD204, which targets PDL1-positive NSCLC, is designed to evaluate the safety and efficacy of this novel radiotherapeutic in eligible individuals with lung cancer.
  • The study will be conducted at Princess Alexandra Hospital in Brisbane, Australia, with the support of leading oncology care provider GenesisCare.
  • The technology underpinning the trial is Radiopharm’s proprietary nanobody from its NanoMab platform, which targets the PDL1 expression in NSCLC, the most common type of lung cancer.
  • Worldwide it was estimated that there are more than 2.2 million cases of lung cancer in 2020², with NSCLC accounting for approximately 85% of all lung cancer cases.

Aquis Stock Exchange: Updated Application for Admission Announcement

Retrieved on: 
Martedì, Ottobre 17, 2023
Housing, Health, Assurance, Government, Main Market, Onitsha, OBE, PAR, Hattie, Risk management, International Business Law Consortium, Assurance services, Education, Measuring Business Excellence, Homelessness, FCCA, THAN, Limited, CLASS, Risk, ICAEW, NHS, AIM, PLC, TIAA, Trust, Charitable organization, Princess Alexandra Hospital, NHS primary care trust, Treasury, SPV, Management, Financial adviser, Security (finance), Health care

Jeffrey has extensive experience as a non-executive director in the commercial, public and voluntary sectors, including as joint chairman of eight NHS Primary Care Trusts.

Key Points: 
  • Jeffrey has extensive experience as a non-executive director in the commercial, public and voluntary sectors, including as joint chairman of eight NHS Primary Care Trusts.
  • Kevin is the CEO of Adsure Services PLC with over 17 years’ experience in internal audit, risk management and governance in a variety of sectors.
  • NAME OF AQUIS CORPORATE ADVISER:
    NUMBER, CLASS AND PAR VALUE OF SECURITIES TO BE ADMITTED:
    10,582,440 Ordinary Shares with a par value of £0.005 per share.
  • SHAREHOLDERS HOLDING MORE THAN FIVE PER CENT OF THE APPLICANT’S SHARE CAPITAL OR VOTING RIGHTS PRE- AND POST-ADMISSION:

Aquis Stock Exchange: Application for Admission Announcement

Retrieved on: 
Lunedì, Ottobre 2, 2023
Treasury, Risk, Housing, PLC, AIM, Measuring Business Excellence, Homelessness, Hattie, Risk management, OBE, Main Market, Onitsha, NHS primary care trust, Government, SPV, Princess Alexandra Hospital, Limited, Assurance services, TIAA, THAN, PAR, ICAEW, CLASS, Education, Charitable organization, Health, NHS, Assurance, Trust, International Business Law Consortium, FCCA, Management, Financial adviser, Security (finance), Health care

Jeffrey has extensive experience as a non-executive director in the commercial, public and voluntary sectors, including as joint chairman of eight NHS Primary Care Trusts.

Key Points: 
  • Jeffrey has extensive experience as a non-executive director in the commercial, public and voluntary sectors, including as joint chairman of eight NHS Primary Care Trusts.
  • Kevin is the CEO of Adsure Services PLC with over 17 years’ experience in internal audit, risk management and governance in a variety of sectors.
  • NAME OF AQUIS CORPORATE ADVISER:
    NUMBER, CLASS AND PAR VALUE OF SECURITIES TO BE ADMITTED:
    10,582,440 Ordinary Shares with a par value of £0.005 per share.
  • SHAREHOLDERS HOLDING MORE THAN FIVE PER CENT OF THE APPLICANT’S SHARE CAPITAL OR VOTING RIGHTS PRE- AND POST-ADMISSION:

Positive Interim Data of BellaSeno's Clinical Trial with Resorbable Breast and Chest Implants Reported at RACS 2023

Retrieved on: 
Martedì, Maggio 9, 2023
Infection, University, Necrosis, Patient satisfaction, Cone Health Women's Hospital, ISO, Clinical trial, Cancer, Quality of life, HBI, CMO, Princess Alexandra Hospital, Elizabeth Wagele, Senior lecturer, Patient, Royal Australasian College of Surgeons, Royal Brisbane and Women's Hospital, RACS, Hospital, Medtech, Royal Australasian College, Polycaprolactone, Medical device, Silk, Medical imaging, Dentistry, Breast

The results were presented at the 91st Annual Scientific Congress 2023 of the Royal Australasian College of Surgeons (RACS) .

Key Points: 
  • The results were presented at the 91st Annual Scientific Congress 2023 of the Royal Australasian College of Surgeons (RACS) .
  • Michael Wagels, Principal Investigator of the first clinical trial evaluating BellaSeno's implant with autologous fat grafting for pectus excavatum camouflage, reported 3-year data from the first in-human case.
  • Not only was the implant safe and well tolerated, but histologic studies demonstrated tissue growth and vascularization within the implant scaffold.
  • Wagels also presented animal data from large 450 ccm scaffolds showing that tissue was fully regenerated in this large volume without the development of necrosis.

The Princess Alexandra NHS Trust Selects Oracle Health Electronic Health Records Platform

Retrieved on: 
Giovedì, Aprile 13, 2023
Acceleration, Oracle, Princess Alexandra Hospital, Princess Alexandra, Patient, EHR, Hospital Insurance and Diagnostic Services Act, Oracle Health Sciences, Trust, Conference, Princess Alexandra Hospital NHS Trust, Hospital, Nursing

AUSTIN, Texas and LONDON, April 13, 2023 /PRNewswire/ --- The Princess Alexandra NHS Trust (PAHT) has signed a ten-year agreement to modernise its hospital systems with Oracle Health electronic health records (EHR). By moving away from multiple legacy digital and paper-based systems to a single EHR platform, Princess Alexandra Hospital in Harlow, England can reduce administrative tasks for hospital staff and help improve the delivery of medications and treatments for patients. It will also help PAHT change how clinicians use data to admit, treat, discharge, and communicate with patients.

Key Points: 
  • AUSTIN, Texas and LONDON, April 13, 2023 /PRNewswire/ --- The Princess Alexandra NHS Trust (PAHT) has signed a ten-year agreement to modernise its hospital systems with Oracle Health electronic health records (EHR).
  • It will also help PAHT change how clinicians use data to admit, treat, discharge, and communicate with patients.
  • "The Oracle Health EHR is a vital component of our huge digital transformation programme," said Phil Holland, chief information officer, The Princess Alexandra Hospital NHS Trust.
  • To learn more about how Oracle is transforming healthcare, visit Booth #921 at the 2023 HIMSS Global Health Conference in Chicago, April 17-21, 2023 and book a meeting here .

The Princess Alexandra Hospital NHS Trust Selects MRI Software to Meet IFRS Lease & Capital Accounting Requirements

Retrieved on: 
Mercoledì, Aprile 12, 2023
Financial services, MRI Software, Disclosure, Trust, Software, Princess Alexandra Hospital, Public sector, MRI, St Margaret's Hospital, Princess Alexandra Hospital NHS Trust, Artificial intelligence, NHS trust, Hospital, Essex Hospital, NHS, Hospital Insurance and Diagnostic Services Act, Property management, Medical device

LONDON, April 12, 2023 /PRNewswire/ -- The Princess Alexandra Hospital NHS Trust has chosen to deploy MRI Software 's IFRS compliant lease and capital accounting solution to improve the day-to-day management and control of its asset base while ensuring compliance with the latest IFRS 16 lease accounting requirements, which became effective for NHS organisations from April 2022.

Key Points: 
  • LONDON, April 12, 2023 /PRNewswire/ -- The Princess Alexandra Hospital NHS Trust has chosen to deploy MRI Software 's IFRS compliant lease and capital accounting solution to improve the day-to-day management and control of its asset base while ensuring compliance with the latest IFRS 16 lease accounting requirements, which became effective for NHS organisations from April 2022.
  • The NHS Trust will replace its spreadsheet-based process to manage and report on its real estate leases under IFRS 16 using MRI's lease accounting solution , MRI ProLease.
  • The Princess Alexandra Hospital NHS Trust will also be leveraging MRI's artificial intelligence (AI) lease abstraction tool, MRI Contract Intelligence, to extract its lease information from documents, validate the data and feed it directly into the lease accounting software, saving valuable time and resource.
  • The key influence in the Trust's decision to select MRI Software was its ability to provide both a capital and lease accounting solution.

POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022

Retrieved on: 
Sabato, Settembre 10, 2022
Terminology, Population, PSMA, Cancer, Company, Actinium-225, Princess Alexandra Hospital, GLOBE, ESMO, Safety, Intention, Poster, Fatigue, Annual report, University, Division, AES, PSA, Private Securities Litigation Reform Act, SEC, Â, Forward-looking statement, Patient, MCRPC, Metro South Health, FACP, COVID-19, SPLASH, Investor, MS, Pharmacokinetics, RPF, Prostate cancer, Associate, Xerostomia, Disclosure, Weill Cornell Medicine, NASDAQ, Progression-free survival, Research, Nausea, Anemia, United Kingdom, PR, CR, Toronto, Risk management, Medical imaging, Pharmaceutical industry, Medicine, MD

INDIANAPOLIS, Sept. 10, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today published a poster at ESMO Congress 2022 containing updated efficacy and safety data from the 27-patient safety and dosimetry lead-in cohort for the Company’s phase 3 SPLASH trial (NCT04647526) evaluating PNT2002 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Key findings include a median rPFS time of 11.5 months, along with a well-tolerated safety profile with no treatment-related deaths and few treatment-related AEs of grade 3 or higher.

Key Points: 
  • rPFS is the primary endpoint of the SPLASH trial, making these positive signals from the lead-in cohort extremely promising, said Dr. Neil Fleshner, Chief Medical Officer of POINT Biopharma.
  • Upcoming third-party coverage of the data will include video interviews of Dr. Fleshner by UroToday, and of Dr. Aaron R. Hansen by VuMedi.
  • The phase 3 SPLASH trial is a multi-center, randomized, open label assessment of PNT2002 in participants with prostate-specific membrane antigen (PSMA)-expressing mCRPC who have progressed on androgen receptor pathway inhibitor (ARPI) therapy.
  • The poster is titled Efficacy and Safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) Therapy in Metastatic Castration Resistant Prostate Cancer (mCRPC): Initial Results from SPLASH (e-Poster #1400P).

POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial

Retrieved on: 
Domenica, Settembre 4, 2022
Prostate cancer, COVID-19, University, Princess Alexandra Hospital, Safety, Cancer, Pharmacokinetics, SPLASH, NASDAQ, Associate, Poster, ESMO, Forward-looking statement, SEC, MCRPC, Actinium-225, GLOBE, Patient, Intention, Progression-free survival, Company, United Kingdom, Terminology, Annual report, Private Securities Litigation Reform Act, PSMA, Pharmaceutical industry, Medicine

An abstract is now available on the ESMO congress website at https://cslide.ctimeetingtech.com/esmo2022/attendee/confcal_2/presentati... , and an e-poster which contains updated data will be published and presented on Sunday, September 11th.

Key Points: 
  • An abstract is now available on the ESMO congress website at https://cslide.ctimeetingtech.com/esmo2022/attendee/confcal_2/presentati... , and an e-poster which contains updated data will be published and presented on Sunday, September 11th.
  • In advance of the publication of the abstract, the Company recently hosted a 45-minute educational webinar entitled Understanding the PNT2002 SPLASH Trial Control Arm.
  • The randomization phase of the study is expected to enroll approximately 400 participants across North America, Europe, and the United Kingdom.
  • Participants will be randomized 2:1 with participants in arm A receiving PNT2002 and participants in arm B receiving either abiraterone or enzalutamide.

BellaSeno Starts Two Clinical Trials of its Resorbable Breast and Chest Implants

Retrieved on: 
Giovedì, Agosto 4, 2022
Medtech, University, BioCity Nottingham, Polycaprolactone, ISO, Senior lecturer, Quality of life, HBI, Pectus excavatum, BMBF, Patient, Company, Pain, Safety, Tissue, Hospital, Regional development, PCL, University of Queensland, SAB, Government, Education, Committee on European Affairs and Oversight of the European Funds, Solution, Health, Certification, Princess Alexandra Hospital, CMO, Princess Alexandra Hospital, Brisbane, Environment, CBCI, Medical device, Medical imaging, Royal Brisbane and Women's Hospital, Research

BellaSeno already published first-in-human data in 2021, demonstrating that its implant was able to camouflage a pectus excavatum defect not reconstructable by conventional techniques.

Key Points: 
  • BellaSeno already published first-in-human data in 2021, demonstrating that its implant was able to camouflage a pectus excavatum defect not reconstructable by conventional techniques.
  • The second trial aims to enroll 20 patients who either need breast implant revision or surgery to correct congenital breast defects.
  • In both trials, patients will receive porous polycaprolactone implants produced in Bellasenos AI-driven additive manufacturing facilities by a no-touch approach.
  • The Company is developing novel resorbable soft tissue and bone reconstruction implants made by additive manufacturing (3D-printing) under ISO 13485 certification.